Fibroblast Activation Protein Inhibitor (FAPI)-PET Imaging in Sarcoma.

PET Clin

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, Germany. Electronic address:

Published: July 2023

Advances in histopathologic and molecular genetic subtyping of sarcoma will potentially allow identification of novel diagnostic and therapeutic targets for specific subtypes, but a "pan-sarcoma" target is needed. This article provides an overview on expression of one potential candidate, fibroblast activation protein alpha in soft tissue and bone sarcoma, and the resulting application of 68Ga-FAPI as novel imaging probes in these rare tumor entities. Current preclinical and clinical data on 68Ga-FAPI-PET/CT in sarcomas are summarized. 68Ga-FAPI-PET-CT potentially offers important complementary information to be used in diagnostic work-up, assessment of therapy response, and prognostication of soft tissue and bone sarcomas.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpet.2023.03.001DOI Listing

Publication Analysis

Top Keywords

fibroblast activation
8
activation protein
8
soft tissue
8
tissue bone
8
protein inhibitor
4
inhibitor fapi-pet
4
fapi-pet imaging
4
imaging sarcoma
4
sarcoma advances
4
advances histopathologic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!